GH-001 is under clinical development by GH Research and currently in Phase II for Post Partum Depression (Maternal Depression / Postnatal Depression). According to GlobalData, Phase II drugs for Post Partum Depression (Maternal Depression / Postnatal Depression) have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GH-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GH-001 is under development for the treatment of treatment-resistant depression, major depressive disorder, bipolar II disorder, post partum depression and other psychiatric diseases. The drug candidate is a 5-methoxy-dimethyltryptamine (5-MEO-DMT). The drug candidate is a drug-device combination. It is administered through the inhalational route. It acts by targeting serotonin 5 HT1A and 5HT2A.
GH Research overview
GH Research biopharmaceutical company developing novel therapies for psychiatric and neurological disorders. The company has desigend its proprietary inhalable 5-MeO-DMT for depression. GH Research is headquartered in Dublin, Ireland.
For a complete picture of GH-001’s drug-specific PTSR and LoA scores, buy the report here.